HOME >> BIOLOGY >> NEWS
Johns Hopkins Scientists Designing Compounds To Fight Malaria

Chemists have developed new compounds that show promise in treating malaria by making the disease-causing parasites self-destruct.

A scientific paper about the compounds will appear in the March 12 issue of the Journal of Medicinal Chemistry, published by the American Chemical Society.

At any given time, about 300 million people suffer from malaria, and as many as 3 million of them, mostly children, will die every year. The most severe form of the infection is caused by tiny parasites called Plasmodium falciparum, which are transmitted by female mosquitos feeding on human blood.

The drug of choice to combat malaria has been chloroquine, a derivative of quinine, which comes from the bark of the Cinchona tree. But the malaria parasites began showing resistance to chloroquine nearly 40 years ago.

Chinese chemists have isolated a new anti-malarial drug from the plant Artemisia annua, which has been used for thousands of years as an herbal remedy for fever. The drug, called artemisinin, has since been proven to be effective against malaria. Chemists have developed derivatives of artemisinin, as well. But artemisinin and its derivatives remain difficult and expensive to produce, and they quickly break down in the human body.

New synthetic compounds being developed at Johns Hopkins have been shown to kill malaria parasites in test tubes and in experiments with mice. Although the synthetic compounds use the same general mechanism as artemisinin, they are not derivatives of the drug; they are a new type of compound that has a much simpler structure. Because they are simpler, they can be made in only three to five chemical steps, compared to 12 or more steps for the artemisinin derivatives.

The research is being conducted by a team of scientists led by Gary H. Posner, Scowe Professor of Chemistry in The Johns Hopkins University School of Arts and Sciences, Theresa A. Sh
'"/>

Contact: Emil Venere
emil@jhu.edu
410-516-7160
Johns Hopkins University
12-Feb-1998


Page: 1 2 3

Related biology news :

1. Yale professor receives Johnson & Johnson Focused Giving award
2. Marian Johnson-Thompson wins 2004 Alice C. Evans Award
3. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
4. Johns Hopkins gene hunters pinpoint new cancer gene target
5. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
6. Johns Hopkins receives $24 million from Donald W. Reynolds Foundation to study sudden cardiac death
7. Johns Hopkins researchers devise methods to evaluate disaster drills
8. Johns Hopkins scientists create forgetful mouse
9. A bed of microneedles: Johns Hopkins scientists gadget measures muscle cell force
10. Wake Forest-Johns Hopkins team discovers prostate cancer gene
11. The next generation of scientists recognized at Johns Hopkins

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Johns Hopkins Scientists Designing Compounds Fight Malaria

(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:11/21/2014)... The report, "Synthetic Biology ... Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, ... Bioremediation) - Global Forecast to 2018", analyses ... opportunities, and challenges. , Browse 99 market ... 185 pages and in-depth TOC of the ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: